Loading clinical trials...
Loading clinical trials...
Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib or Gemcitabine in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)
Conditions
Interventions
RP-3500 (camonsertib)
Talazoparib
+1 more
Locations
13
United States
#1014, Northwestern University
Chicago, Illinois, United States
#1006, Massachusetts General Hospital
Boston, Massachusetts, United States
#1002, Dana Farber Cancer Institute
Boston, Massachusetts, United States
#1004, Memorial Sloan Kettering Cancer Institute
New York, New York, United States
#1005, Duke Cancer Institute
Durham, North Carolina, United States
#1007, Rhode Island Hospital
Providence, Rhode Island, United States
Start Date
July 22, 2020
Primary Completion Date
June 13, 2025
Completion Date
June 13, 2025
Last Updated
October 21, 2025
NCT05720117
NCT06898450
NCT05719558
NCT05098132
NCT07477743
NCT07029399
Lead Sponsor
Repare Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions